Drug intelligence / Profile preview

IVAC_M

Development stage: Phase 1
Lead developer: BioNTech
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

IVAC_M is an individualized RNA vaccine developed by BioNTech SE. It is designed as an Individualized NeoAntigen Specific Immunotherapy (iNeST) that encodes neoepitopes derived from up to 20 cancer mutations, determined by Next-Generation Sequencing (NGS). This liposome-formulated intravenous vaccine aims to treat patients with relevant and immunogenic RNA vaccines for their specific tumor, particularly in triple-negative breast cancer.

Other names: Individualized NeoAntigen Specific ImmunotherapyiNeST

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on IVAC_M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVAC_M.

Explore the full profile